{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:34:41Z","timestamp":1793237681201,"version":"4.5.0"},"reference-count":173,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jhepr.2026.102021","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:15:09Z","timestamp":1788480909000},"page":"102021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative strategies for the treatment of HCC"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9164-3671","authenticated-orcid":false,"given":"Antonio","family":"D\u2019Alessio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6395-490X","authenticated-orcid":false,"given":"Felix J.","family":"Krendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Parente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Guerra Veloz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parissa","family":"Tabrizian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.102021_bib1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib2","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102021_bib3","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/bjs.8915","article-title":"Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria","volume":"99","author":"Lim","year":"2012","journal-title":"Br J Surg"},{"key":"10.1016\/j.jhepr.2026.102021_bib4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1440-1746.2011.06947.x","article-title":"Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis","volume":"27","author":"Li","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib5","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/SLA.0000000000000710","article-title":"Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis","volume":"261","author":"Tabrizian","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhepr.2026.102021_bib6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0168-8278(02)00360-4","article-title":"Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy","volume":"38","author":"Imamura","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/jamasurg.2018.4334","article-title":"Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China","volume":"154","author":"Xu","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jhepr.2026.102021_bib8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2026.102021_bib9","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/TP.0000000000003174","article-title":"Liver transplantation for hepatocellular carcinoma. Working group report from the ILTS transplant oncology consensus conference","volume":"104","author":"Mehta","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.jhepr.2026.102021_bib10","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.102021_bib11","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib12","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"0","author":"Abou-Alfa Ghassan","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhepr.2026.102021_bib13","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.jhepr.2026.102021_bib14","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.jhepr.2026.102021_bib15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.jhepr.2026.102021_bib16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.jhepr.2026.102021_bib17","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.annonc.2025.05.542","volume":"36","author":"Dong","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.102021_bib18","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1200\/JCO.2026.44.16_suppl.4001","article-title":"Camrelizumab (C) plus rivoceranib (R) with transarterial chemoembolization (TACE) vs. TACE alone in unresectable hepatocellular carcinoma (uHCC): a randomized, phase 3 trial","volume":"44","author":"Jia","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.102021_bib19","volume":"44","author":"Abou-Alfa","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.102021_bib20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.102021_bib21","article-title":"Liver resection and transplantation in the era of checkpoint inhibitors","volume":"6","author":"Tabrizian","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.102021_bib22","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2026.102021_bib23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhepr.2026.102021_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.102021_bib25","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.immuni.2023.09.004","article-title":"Cancer cell-intrinsic mechanisms driving acquired immune tolerance","volume":"56","author":"Ghorani","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.jhepr.2026.102021_bib26","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s43018-025-00986-3","article-title":"The tumor microenvironment's role in the response to immune checkpoint blockade","volume":"6","author":"Aliazis","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jhepr.2026.102021_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2026.102021_bib28","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2026.102021_bib29","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2026.102021_bib30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41591-022-02189-0","article-title":"Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial","volume":"29","author":"Cascone","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.102021_bib31","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","article-title":"Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy","volume":"185","author":"Luoma","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jhepr.2026.102021_bib32","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ccell.2025.02.026","article-title":"Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies","volume":"43","author":"Li","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2026.102021_bib33","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","article-title":"Spatial predictors of immunotherapy response in triple-negative breast cancer","volume":"621","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2026.102021_bib34","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41591-025-03512-1","article-title":"Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma","volume":"31","author":"Long","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.102021_bib35","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.102021_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009722","article-title":"Immune checkpoint blockade: timing is everything","volume":"12","author":"Sinicrope","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhepr.2026.102021_bib37","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s43018-025-00990-7","article-title":"The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types","volume":"6","author":"Awada","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jhepr.2026.102021_bib38","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41591-020-0829-0","article-title":"Learning from clinical trials of neoadjuvant checkpoint blockade","volume":"26","author":"Versluis","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.102021_bib39","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.102021_bib40","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.102021_bib41","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.annonc.2023.01.004","article-title":"Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials","volume":"34","author":"Versluis","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.102021_bib42","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41591-022-01681-x","article-title":"Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery","volume":"28","author":"Marron","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.102021_bib43","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","article-title":"Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity","volume":"2","author":"Ho","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jhepr.2026.102021_bib44","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","article-title":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","volume":"7","author":"Marron","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib45","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41590-024-01992-w","article-title":"Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma","volume":"25","author":"Shu","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhepr.2026.102021_bib46","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","article-title":"Intratumoral dendritic cell\u2013CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma","volume":"29","author":"Magen","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.102021_bib47","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41571-019-0319-9","article-title":"Harnessing cancer immunotherapy during the unexploited immediate perioperative period","volume":"17","author":"Matzner","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.102021_bib48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ebiom.2019.07.058","article-title":"Hepatectomy promotes recurrence of liver cancer by enhancing IL-11-STAT3 signaling","volume":"46","author":"Wang","year":"2019","journal-title":"eBioMedicine"},{"key":"10.1016\/j.jhepr.2026.102021_bib49","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib50","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12885-021-08033-x","article-title":"PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma","volume":"21","author":"Pinato","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhepr.2026.102021_bib51","article-title":"Neoadjuvant nivolumab plus ipilimumab in surgically resectable hepatocellular carcinoma (PRIME-HCC): a prospective, phase 1b, single-arm trial and translational analyses","author":"D\u2019Alessio","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.102021_bib52","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1038\/s41467-024-47420-3","article-title":"Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.102021_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004656","article-title":"Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial","volume":"10","author":"Xia","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhepr.2026.102021_bib54","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/S0140-6736(25)01720-9","article-title":"Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2\/3 trial","volume":"406","author":"Wang","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.jhepr.2026.102021_bib55","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/s41467-025-68108-2","article-title":"Perioperative tislelizumab plus lenvatinib treatment for resectable hepatocellular carcinoma at high risk of recurrence: single-arm phase II trial","volume":"17","author":"Chen","year":"2026","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.102021_bib56","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jhep.2025.08.035","article-title":"Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration","volume":"84","author":"Lin","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib57","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/HEP.0000000000001026","article-title":"Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: the impact of successful antiviral treatment","volume":"81","author":"Celsa","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102021_bib58","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(24)00457-1","article-title":"Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis","volume":"25","author":"D'Alessio","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.102021_bib59","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update","volume":"84","author":"Reig","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib60","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/hep.27288","article-title":"Earlier presentation and application of curative treatments in hepatocellular carcinoma","volume":"60","author":"Ulahannan","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102021_bib61","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.102021_bib62","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S2468-1253(24)00434-5","article-title":"Precision surgery for hepatocellular carcinoma","volume":"10","author":"Magyar","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib63","unstructured":"Zorigtbaatar A, Moral K, Sapisochin G, et al. Recent advances in therapeutic and surgical approaches in locally advanced HCC: downstaging and neoadjuvant therapy. Int J Surg 9900:10.1097\/JS9.0000000000004958."},{"key":"10.1016\/j.jhepr.2026.102021_bib64","article-title":"Oncological resectability criteria for hepatocellular carcinoma in the era of novel systemic therapies: the Japan liver cancer association and Japanese society of hepato-biliary-pancreatic surgery expert consensus statement 2023","volume":"13","author":"Akahoshi","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2026.102021_bib65","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S2468-1253(19)30178-5","article-title":"Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west","volume":"4","author":"Lu","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib66","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/HEP.0000000000000726","article-title":"Adjuvant and neoadjuvant therapies for hepatocellular carcinoma","volume":"82","author":"Vogel","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102021_bib67","doi-asserted-by":"crossref","first-page":"227","DOI":"10.21037\/hbsn-21-328","article-title":"Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)","volume":"11","author":"Sun","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.jhepr.2026.102021_bib68","article-title":"Hepatocellular carcinoma and liver transplant: what about neo- and adjuvant immunotherapy","author":"Khalaf","year":"2025","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.jhepr.2026.102021_bib69","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s00595-020-02088-2","article-title":"Issues to be considered to address the future liver remnant prior to major hepatectomy","volume":"51","author":"Kishi","year":"2021","journal-title":"Surg Today"},{"key":"10.1016\/j.jhepr.2026.102021_bib70","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/0003134820951451","article-title":"The future liver remnant : definition, evaluation, and management","volume":"87","author":"Dixon","year":"2021","journal-title":"Am Surg"},{"key":"10.1016\/j.jhepr.2026.102021_bib71","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00270-012-0440-y","article-title":"Portal vein embolization before liver resection: a systematic review","volume":"36","author":"van Lienden","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jhepr.2026.102021_bib72","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/SLA.0000000000003433","article-title":"ALPPS versus portal vein embolization for hepatitis-related hepatocellular carcinoma: a changing paradigm in modulation of future liver remnant before major hepatectomy","volume":"273","author":"Chan","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhepr.2026.102021_bib73","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1097\/SLA.0000000000001087","article-title":"Is partial-ALPPS safer than ALPPS? A single-center experience","volume":"261","author":"Petrowsky","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhepr.2026.102021_bib74","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00423-016-1424-1","article-title":"Inverting the ALPPS paradigm by minimizing first stage impact: the Mini-ALPPS technique","volume":"401","author":"de Santiba\u00f1es","year":"2016","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.jhepr.2026.102021_bib75","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1007\/s00268-014-2513-3","article-title":"ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies: results of a multicenter analysis","volume":"38","author":"Schadde","year":"2014","journal-title":"World J Surg"},{"key":"10.1016\/j.jhepr.2026.102021_bib76","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.hpb.2022.02.007","article-title":"softALPPS - a novel, individual procedure for patients with advanced liver tumors","volume":"24","author":"Steffani","year":"2022","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhepr.2026.102021_bib77","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1007\/s00330-016-4291-9","article-title":"Simultaneous trans-hepatic portal and hepatic vein embolization before major hepatectomy: the liver venous deprivation technique","volume":"26","author":"Guiu","year":"2016","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jhepr.2026.102021_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2022.101812","article-title":"Liver venous deprivation versus associating liver partition and portal vein ligation for staged hepatectomy for colo-rectal liver metastases: a comparison of early and late kinetic growth rates, and perioperative and oncological outcomes","volume":"43","author":"Cassese","year":"2022","journal-title":"Surg Oncol"},{"key":"10.1016\/j.jhepr.2026.102021_bib79","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000288","article-title":"Contemporary applications of Y90 for the treatment of hepatocellular carcinoma","volume":"7","author":"Yu","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2026.102021_bib80","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1200\/JCO-25-01796","article-title":"Transarterial chemoembolization combined with camrelizumab and rivoceranib for unresectable hepatocellular carcinoma (CHANCE2005\/CARES-005): a randomized phase II trial","volume":"44","author":"Zhu","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.102021_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100635","article-title":"A new standard for HCC: the high stakes of TACE-immunotherapy combinations","author":"D'Alessio","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.jhepr.2026.102021_bib82","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","article-title":"Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial","volume":"8","author":"Chiang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib83","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007366","article-title":"Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial","volume":"11","author":"Zhang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhepr.2026.102021_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102367","article-title":"Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study","volume":"67","author":"Wu","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jhepr.2026.102021_bib85","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41392-025-02498-z","article-title":"Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study","volume":"11","author":"Zhang","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jhepr.2026.102021_bib86","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1186\/s12885-024-12772-y","article-title":"Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"24","author":"Xu","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhepr.2026.102021_bib87","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001723","article-title":"The rise of transplant oncology in primary liver cancer and metastatic disease","author":"Wassmer","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102021_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184574","article-title":"Immunotherapy and liver transplantation: a narrative review of basic and clinical data","volume":"15","author":"Wassmer","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhepr.2026.102021_bib89","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102021_bib90","first-page":"779","article-title":"Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma","volume":"157","author":"Tabrizian","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jhepr.2026.102021_bib91","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jvir.2024.10.034","article-title":"Yttrium-90 radioembolization has become the most utilized bridging treatment for liver transplant candidates in the United States","volume":"36","author":"Salem","year":"2025","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jhepr.2026.102021_bib92","article-title":"Yttrium-90 radioembolization is associated with a lower risk of liver transplant waitlist dropout than chemoembolization in hepatocellular carcinoma","author":"Kim","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib93","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2021.07.033","article-title":"Downstaging outcomes for hepatocellular carcinoma: results from the multicenter evaluation of reduction in tumor size before liver transplantation (MERITS-LT) consortium","volume":"161","author":"Mehta","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.102021_bib94","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/HEP.0000000000001231","article-title":"Downstaging of hepatocellular carcinoma before liver transplantation: results from a national multicenter prospective cohort study","volume":"82","author":"Xu","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102021_bib95","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1470-2045(20)30224-2","article-title":"Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b\/3 trial","volume":"21","author":"Mazzaferro","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.102021_bib96","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/hep.31223","article-title":"Effect of mandatory 6-month waiting period on waitlist and transplant outcomes in patients with hepatocellular carcinoma","volume":"72","author":"Nagai","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102021_bib97","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/HEP.0000000000000668","article-title":"Benefit and harm of waiting time in liver transplantation for HCC","volume":"82","author":"van der Meeren","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102021_bib98","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1097\/TP.0000000000001752","article-title":"Wait time of less than 6 and greater than 18 Months predicts hepatocellular carcinoma recurrence after liver transplantation: proposing a wait time \"sweet spot\"","volume":"101","author":"Mehta","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.jhepr.2026.102021_bib99","article-title":"Impact of waiting time on post-transplant survival for recipients with hepatocellular carcinoma: a natural experiment randomized by blood group","volume":"5","author":"Beumer","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.102021_bib100","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jhep.2024.03.019","article-title":"Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC study","volume":"81","author":"Lamarque","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib101","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/lt.25317","article-title":"Increasing liver transplantation wait-list dropout for hepatocellular carcinoma with widening geographical disparities: implications for organ allocation","volume":"24","author":"Mehta","year":"2018","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2026.102021_bib102","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/lt.26368","article-title":"The impact of median model for end-stage liver disease at transplant minus 3 national policy on waitlist outcomes in patients with and without hepatocellular carcinoma","volume":"28","author":"Bernards","year":"2022","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2026.102021_bib103","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.cgh.2021.07.048","article-title":"National trends and waitlist outcomes of locoregional therapy among liver transplant candidates with hepatocellular carcinoma in the United States","volume":"20","author":"Kwong","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib104","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/ajt.15617","article-title":"Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?","volume":"20","author":"Nordness","year":"2020","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhepr.2026.102021_bib105","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/hep.31234","article-title":"Immunotherapy as a downstaging therapy for liver transplantation","volume":"72","author":"Schwacha-Eipper","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102021_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2021.101386","article-title":"Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period","volume":"66","author":"Chen","year":"2021","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.jhepr.2026.102021_bib107","doi-asserted-by":"crossref","first-page":"9354","DOI":"10.21037\/apm-21-999","article-title":"Prognosis after liver transplantation in patients treated with anti-PD-1 immunotherapy for advanced hepatocellular carcinoma: case series","volume":"10","author":"Chen","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.jhepr.2026.102021_bib108","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1007\/s12328-021-01521-4","article-title":"Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy","volume":"14","author":"Dehghan","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.102021_bib109","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.14309\/ajg.0000000000001391","article-title":"Immunotherapy as a downstaging tool for liver transplantation in hepatocellular carcinoma","volume":"116","author":"Lizaola-Mayo","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.102021_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.653437","article-title":"Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: a cohort study and literature review","volume":"12","author":"Qiao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2026.102021_bib111","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1097\/TP.0000000000003855","article-title":"Durvalumab as a successful downstaging therapy for liver transplantation in hepatocellular carcinoma: the importance of a washout period","volume":"105","author":"Sogbe","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.jhepr.2026.102021_bib112","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/ajt.16448","article-title":"PD-1 inhibitor as bridge therapy to liver transplantation?","volume":"21","author":"Tabrizian","year":"2021","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhepr.2026.102021_bib113","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1111\/ajt.16965","article-title":"Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab","volume":"22","author":"Schnickel","year":"2022","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhepr.2026.102021_bib114","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001304","article-title":"Immune checkpoint inhibitor therapy before liver transplantation\u2014case and literature review","volume":"8","author":"Aby","year":"2022","journal-title":"Transplant Direct"},{"key":"10.1016\/j.jhepr.2026.102021_bib115","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.3390\/curroncol29060341","article-title":"Immunotherapy as a neoadjuvant therapy for a patient with hepatocellular carcinoma in the pretransplant setting: a case report","volume":"29","author":"Abdelrahim","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jhepr.2026.102021_bib116","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14209","article-title":"Stable liver graft post anti-PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma","volume":"26","author":"Kang","year":"2022","journal-title":"Pediatr Transpl"},{"key":"10.1016\/j.jhepr.2026.102021_bib117","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1097\/TP.0000000000004108","article-title":"The impact of treatment of hepatocellular carcinoma with immune checkpoint inhibitors on pre- and post-liver transplant outcomes","volume":"106","author":"Dave","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.jhepr.2026.102021_bib118","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/LVT.0000000000000083","article-title":"Neoadjuvant programmed cell death 1 inhibitor before liver transplantation for HCC is not associated with increased graft loss","volume":"29","author":"Wang","year":"2023","journal-title":"Liver Transplant : official Publ Am Assoc Study Liver Dis Int Liver Transplant Soc"},{"key":"10.1016\/j.jhepr.2026.102021_bib119","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.21037\/jgo-22-922","article-title":"Immune checkpoint inhibitors in liver transplant: a case series","volume":"14","author":"Rudolph","year":"2023","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.jhepr.2026.102021_bib120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1205997","article-title":"Case Report: successful liver transplantation after achieving complete clinical remission of advanced HCC with Atezolizumab plus Bevacizumab combination therapy","volume":"14","author":"Chouik","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2026.102021_bib121","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.3390\/jcm13113068","article-title":"Utilization of immunotherapy as a neoadjuvant therapy for liver transplant recipients with hepatocellular carcinoma","volume":"13","author":"Abdelrahim","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jhepr.2026.102021_bib122","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ajt.2024.01.007","article-title":"Atezolizumab plus bevacizumab as a downstaging therapy for liver transplantation in hepatocellular carcinoma with portal vein thrombosis: the first report","volume":"24","author":"Kumar","year":"2024","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhepr.2026.102021_bib123","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00262-024-03853-9","article-title":"Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation","volume":"74","author":"Lu","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jhepr.2026.102021_bib124","doi-asserted-by":"crossref","first-page":"6647","DOI":"10.1097\/JS9.0000000000001813","article-title":"Pembrolizumab in combination with LEnvatinib in participants with hepatocellular carcinoma before liver transplant as Neoadjuvant TherapY-PLENTY pilot study","volume":"110","author":"Lv","year":"2024","journal-title":"Int J Surg"},{"key":"10.1016\/j.jhepr.2026.102021_bib125","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ajt.2024.04.007","article-title":"Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: a multicenter, retrospective cohort study","volume":"24","author":"Guo","year":"2024","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhepr.2026.102021_bib126","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.livres.2025.03.001","article-title":"Short-term prognosis of recipients with pretransplant exposure to immune checkpoint inhibitors after liver transplantation for hepatocellular carcinoma: a retrospective cohort study","volume":"9","author":"Pang","year":"2025","journal-title":"Liver Res"},{"key":"10.1016\/j.jhepr.2026.102021_bib127","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/HEP.0000000000001289","article-title":"Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: an international retrospective cohort study","volume":"82","author":"Moeckli","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102021_bib128","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jhep.2024.06.042","article-title":"Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: a systematic review and individual patient data meta-analysis","volume":"82","author":"Rezaee-Zavareh","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib129","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jhep.2024.09.003","article-title":"Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study","volume":"82","author":"Tabrizian","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib130","article-title":"Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study","author":"Fang","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.102021_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2026.02.019","article-title":"Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL)","author":"Bhoori","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib132","article-title":"Safety of immune checkpoint inhibitors prior to liver transplantation in hepatocellular carcinoma","author":"Aceituno","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2026.102021_bib133","article-title":"Transplant oncology \u2013 current indications and strategies to advance the field","volume":"6","author":"Krendl","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.102021_bib134","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/SLA.0000000000003253","article-title":"Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma: analysis from the US multicenter HCC transplant consortium","volume":"271","author":"DiNorcia","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhepr.2026.102021_bib135","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1097\/TP.0000000000003162","article-title":"Experience with LDLT in patients with hepatocellular carcinoma and portal vein tumor thrombosis postdownstaging","volume":"104","author":"Soin","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.jhepr.2026.102021_bib136","article-title":"Liver transplantation for HCC with macrovascular invasion: a systematic review and meta-analysis of observational studies","volume":"8","author":"Ladak","year":"2026","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.102021_bib137","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2025.43.4_suppl.633","article-title":"Use of pathological response versus RECIST assessment in predicting relapse-free survival following neoadjuvant immunotherapy for hepatocellular carcinoma","volume":"43","author":"D'Alessio","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.102021_bib138","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s12957-024-03645-6","article-title":"Non-surgery strategy versus hepatectomy in hepatocellular carcinoma patients with complete response after conversion therapy: a meta-analysis","volume":"22","author":"Wang","year":"2024","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.jhepr.2026.102021_bib139","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/JS9.0000000000000942","article-title":"Survival benefit of liver resection following complete response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a retrospective, multicenter, cohort study","volume":"110","author":"Hu","year":"2024","journal-title":"Int J Surg"},{"key":"10.1016\/j.jhepr.2026.102021_bib140","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1097\/JS9.0000000000001155","article-title":"Watch-and-wait strategy vs. resection in patients with radiologic complete response after conversion therapy for initially unresectable hepatocellular carcinoma: a propensity score-matching comparative study","volume":"110","author":"Li","year":"2024","journal-title":"Int J Surg"},{"key":"10.1016\/j.jhepr.2026.102021_bib141","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jamcollsurg.2014.12.030","article-title":"Surgical treatment of hepatocellular carcinoma in North America: can hepatic resection still be justified?","volume":"220","author":"Chapman","year":"2015","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jhepr.2026.102021_bib142","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib143","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/HEP.0000000000001269","article-title":"Critical Update: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"82","author":"Taddei","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102021_bib144","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.102021_bib145","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.102021_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2026.01.006","article-title":"Updated data from IMbrave050: adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma","author":"Yopp","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib147","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1200\/JCO.2026.44.2_suppl.477","article-title":"Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: the phase 3 keynote-937 study","volume":"44","author":"Chan","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.102021_bib148","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1001\/jamasurg.2024.0506","article-title":"Adjuvant transarterial chemoembolization with sorafenib for portal vein tumor thrombus: a randomized clinical trial","volume":"159","author":"Peng","year":"2024","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jhepr.2026.102021_bib149","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.hpb.2019.12.013","article-title":"A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma","volume":"22","author":"Chen","year":"2020","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhepr.2026.102021_bib150","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41591-023-02786-7","article-title":"Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.102021_bib151","doi-asserted-by":"crossref","first-page":"78","DOI":"10.21037\/hbsn-21-350","article-title":"Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients","volume":"11","author":"Koh","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.jhepr.2026.102021_bib152","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.jhepr.2026.102021_bib153","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/SLA.0000000000004280","article-title":"mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors","volume":"272","author":"Schnitzbauer","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhepr.2026.102021_bib154","article-title":"Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma","volume":"7","author":"Tabrizian","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.102021_bib155","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/LVT.0000000000000550","article-title":"Immune checkpoint inhibitors in the posttransplant landscape of HCC: a systematic literature review","volume":"32","author":"Kahramangil","year":"2026","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2026.102021_bib156","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/liv.15419","article-title":"Immune checkpoint inhibitors in malignancies after liver transplantation: a systematic review and pooled analysis","volume":"43","author":"Kayali","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.102021_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajt.2026.02.024","article-title":"Expert consensus on the use of immune checkpoint inhibitors in the liver transplant setting: guidance from the liver transplant committee of the Italian association for the study of the liver (AISF)","author":"Ponziani","year":"2026","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhepr.2026.102021_bib158","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jhep.2023.01.030","article-title":"Liver transplantation immunology: immunosuppression, rejection, and immunomodulation","volume":"78","author":"Montano-Loza","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.2099","article-title":"1469MO Liver resection versus continued atezolizumab plus bevacizumab (atezo\/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo\/bev treatment (TALENTop): a multicenter, open-label, randomized phase III trial","volume":"36","author":"Sun","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.102021_bib160","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.ajt.2023.07.021","article-title":"Downstaging hepatocellular carcinoma before liver transplantation: a multicenter analysis of the \u201call-comers\u201d protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium","volume":"23","author":"Natarajan","year":"2023","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhepr.2026.102021_bib161","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1200\/JCO.2023.41.16_suppl.4129","article-title":"Neoadjuvant immunotherapy with ipilimumab plus nivolumab and radiologically and pathologically quantifiable responses through modulation of the tumour microenvironment in resectable hepatocellular carcinoma","volume":"41","author":"D'Alessio","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.102021_bib162","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jhep.2024.01.011","article-title":"Immunotherapy and transplantation for hepatocellular carcinoma","volume":"80","author":"Tabrizian","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib163","first-page":"815","article-title":"The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinoma","volume":"31","author":"Kodali","year":"2025","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2026.102021_bib164","article-title":"Personalized MRD assessment in perisurgical ctDNA for prognostic prediction in hepatocellular carcinoma","volume":"OF1\u2013OF10","author":"Hu","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhepr.2026.102021_bib165","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1136\/gutjnl-2024-331956","article-title":"Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments","volume":"73","author":"Campani","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.102021_bib166","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-24-0177","article-title":"Safety and preliminary efficacy of pembrolizumab following transarterial chemoembolization for hepatocellular carcinoma: the PETAL phase Ib study","volume":"30","author":"Pinato","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhepr.2026.102021_bib167","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/j.gastro.2022.09.005","article-title":"Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma","volume":"164","author":"Haber","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.102021_bib168","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.102021_bib169","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2025.04.017","article-title":"Machine learning based radiomic models outperform clinical biomarkers in predicting outcomes after immunotherapy for hepatocellular carcinoma","volume":"83","author":"Vithayathil","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102021_bib170","article-title":"Radiomics analysis based on dynamic contrast-enhanced MRI for predicting early recurrence after hepatectomy in hepatocellular carcinoma patients","volume":"15","author":"Wang","year":"2025","journal-title":"Scientific Rep"},{"key":"10.1016\/j.jhepr.2026.102021_bib171","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41392-024-01991-1","article-title":"Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jhepr.2026.102021_bib172","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000535514","article-title":"A multicenter phase 2 trial evaluating the efficacy and safety of preoperative lenvatinib therapy for patients with advanced hepatocellular carcinoma (LENS-HCC trial)","volume":"13","author":"Ichida","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2026.102021_bib173","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071243","article-title":"Everolimus mitigates the risk of hepatocellular carcinoma recurrence after liver transplantation","volume":"16","author":"De Simone","year":"2024","journal-title":"Cancers (Basel)"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:24:14Z","timestamp":1793237054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926002922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":173,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2589555926002922"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102021","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative strategies for the treatment of HCC","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"102021"}}